Pacific Biosciences of California (PACB) Set to Release Quarterly Earnings on Tuesday

Pacific Biosciences of California (NASDAQ:PACB) is expected to post its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.1260) per share and revenue of $43.82 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Pacific Biosciences of California (NASDAQ:PACB) last issued its quarterly earnings results on Monday, August 3rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The business had revenue of $39.01 million during the quarter, compared to analyst estimates of $42.90 million. Pacific Biosciences of California had a negative net margin of 82.49% and a negative return on equity of 5,752.12%. On average, analysts expect Pacific Biosciences of California to post ($0.52) EPS for the current fiscal year and ($0.48) EPS for the next fiscal year.

Pacific Biosciences of California Stock Performance

Pacific Biosciences of California stock opened at $2.25 on Tuesday. The stock has a market capitalization of $699.37 million, a price-to-earnings ratio of -5.23 and a beta of 2.19. Pacific Biosciences of California has a 52-week low of $1.07 and a 52-week high of $3.43. The stock’s 50 day moving average price is $1.71 and its two-hundred day moving average price is $1.60.

Analyst Ratings Changes

PACB has been the topic of a number of research reports. Wall Street Zen downgraded shares of Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. UBS Group initiated coverage on shares of Pacific Biosciences of California in a report on Wednesday, September 9th. They issued a “neutral” rating and a $1.35 price target for the company. Finally, Weiss Ratings raised shares of Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $1.71.

Insider Activity at Pacific Biosciences of California

In other Pacific Biosciences of California news, insider Mark Van Oene sold 26,911 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1.13, for a total value of $30,409.43. Following the completion of the sale, the insider owned 2,705,853 shares of the company’s stock, valued at approximately $3,057,613.89. This trade represents a 0.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James Gibson, II sold 661,815 shares of the business’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total value of $2,058,244.65. Following the sale, the insider owned 1,083,848 shares of the company’s stock, valued at approximately $3,370,767.28. This represents a 37.91% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is currently owned by corporate insiders.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.